| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 233 | 2024 | 20822 | 9.130 |
Why?
|
| Receptor, erbB-2 | 68 | 2023 | 2416 | 5.910 |
Why?
|
| Aromatase Inhibitors | 29 | 2021 | 491 | 4.410 |
Why?
|
| Antineoplastic Agents, Hormonal | 34 | 2022 | 1524 | 4.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 81 | 2023 | 11524 | 3.740 |
Why?
|
| Chemotherapy, Adjuvant | 73 | 2022 | 3479 | 3.640 |
Why?
|
| Tamoxifen | 29 | 2022 | 981 | 3.370 |
Why?
|
| Medical Oncology | 32 | 2023 | 2265 | 3.360 |
Why?
|
| Receptors, Estrogen | 29 | 2024 | 2187 | 3.260 |
Why?
|
| Antineoplastic Agents | 62 | 2021 | 13695 | 2.460 |
Why?
|
| Receptors, Progesterone | 18 | 2022 | 1097 | 2.190 |
Why?
|
| Paclitaxel | 28 | 2023 | 1708 | 1.930 |
Why?
|
| Neoadjuvant Therapy | 23 | 2023 | 2728 | 1.680 |
Why?
|
| Quinazolines | 12 | 2014 | 1356 | 1.490 |
Why?
|
| Genes, erbB-2 | 7 | 2014 | 162 | 1.300 |
Why?
|
| Neoplasms | 32 | 2022 | 21683 | 1.250 |
Why?
|
| Antibodies, Monoclonal | 30 | 2011 | 9274 | 1.200 |
Why?
|
| Ovary | 6 | 2016 | 981 | 1.130 |
Why?
|
| Practice Guidelines as Topic | 19 | 2021 | 7279 | 1.130 |
Why?
|
| Neoplasm Staging | 49 | 2022 | 11031 | 1.120 |
Why?
|
| Female | 232 | 2024 | 380194 | 1.040 |
Why?
|
| Disease-Free Survival | 38 | 2022 | 6895 | 1.030 |
Why?
|
| Estrogen Receptor alpha | 2 | 2023 | 577 | 1.020 |
Why?
|
| Vinblastine | 11 | 2013 | 502 | 0.970 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2023 | 9239 | 0.950 |
Why?
|
| Humans | 289 | 2024 | 744343 | 0.920 |
Why?
|
| Postmenopause | 14 | 2022 | 2461 | 0.890 |
Why?
|
| Cyclophosphamide | 17 | 2023 | 2242 | 0.870 |
Why?
|
| Carcinoma | 7 | 2011 | 2375 | 0.860 |
Why?
|
| Taxoids | 7 | 2011 | 666 | 0.850 |
Why?
|
| Anthracyclines | 5 | 2013 | 288 | 0.830 |
Why?
|
| Androstadienes | 6 | 2018 | 346 | 0.780 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2019 | 170 | 0.770 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2020 | 129 | 0.770 |
Why?
|
| Mastectomy, Segmental | 11 | 2019 | 956 | 0.730 |
Why?
|
| Clinical Trials as Topic | 20 | 2022 | 7913 | 0.710 |
Why?
|
| Drug Approval | 6 | 2018 | 742 | 0.680 |
Why?
|
| Nitriles | 6 | 2021 | 956 | 0.660 |
Why?
|
| Neoplasm Metastasis | 23 | 2020 | 4851 | 0.640 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2012 | 2038 | 0.630 |
Why?
|
| Triazoles | 6 | 2021 | 911 | 0.630 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2013 | 106 | 0.630 |
Why?
|
| Mastectomy | 21 | 2022 | 1793 | 0.620 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2011 | 5172 | 0.580 |
Why?
|
| Indoles | 4 | 2010 | 1839 | 0.570 |
Why?
|
| Premenopause | 12 | 2022 | 1033 | 0.560 |
Why?
|
| Neutropenia | 4 | 2023 | 895 | 0.550 |
Why?
|
| Receptors, Steroid | 2 | 2014 | 155 | 0.550 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2022 | 538 | 0.550 |
Why?
|
| Expert Testimony | 4 | 2019 | 356 | 0.540 |
Why?
|
| Carcinoma, Ductal, Breast | 7 | 2020 | 1101 | 0.540 |
Why?
|
| Patient Selection | 5 | 2019 | 4215 | 0.530 |
Why?
|
| Cancer Care Facilities | 3 | 2013 | 402 | 0.530 |
Why?
|
| Doxorubicin | 15 | 2020 | 2234 | 0.520 |
Why?
|
| Piperazines | 3 | 2022 | 2488 | 0.520 |
Why?
|
| Arthralgia | 3 | 2008 | 456 | 0.500 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 322 | 0.500 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2009 | 415 | 0.490 |
Why?
|
| Deoxycytidine | 7 | 2009 | 826 | 0.480 |
Why?
|
| Biomedical Research | 4 | 2017 | 3309 | 0.480 |
Why?
|
| Lymphatic Metastasis | 9 | 2022 | 2924 | 0.480 |
Why?
|
| Pyridines | 3 | 2022 | 2825 | 0.470 |
Why?
|
| Pyrroles | 3 | 2010 | 1146 | 0.470 |
Why?
|
| Combined Modality Therapy | 19 | 2023 | 8642 | 0.470 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2006 | 648 | 0.460 |
Why?
|
| Endocrine System | 1 | 2014 | 113 | 0.450 |
Why?
|
| Estradiol | 4 | 2019 | 2020 | 0.450 |
Why?
|
| Thoracic Wall | 1 | 2015 | 203 | 0.450 |
Why?
|
| Prognosis | 28 | 2022 | 29063 | 0.450 |
Why?
|
| Cost Control | 1 | 2015 | 624 | 0.430 |
Why?
|
| Mass Media | 3 | 2011 | 305 | 0.420 |
Why?
|
| Continuity of Patient Care | 3 | 2011 | 1049 | 0.420 |
Why?
|
| Treatment Outcome | 43 | 2021 | 63114 | 0.410 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2022 | 949 | 0.410 |
Why?
|
| Survivors | 5 | 2013 | 2291 | 0.410 |
Why?
|
| Drug Administration Schedule | 14 | 2017 | 4933 | 0.410 |
Why?
|
| Communication | 3 | 2011 | 3749 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2018 | 9959 | 0.400 |
Why?
|
| Off-Label Use | 1 | 2013 | 169 | 0.400 |
Why?
|
| Furans | 2 | 2020 | 194 | 0.400 |
Why?
|
| Middle Aged | 82 | 2023 | 213383 | 0.400 |
Why?
|
| Ketones | 2 | 2020 | 188 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 8428 | 0.390 |
Why?
|
| Aged | 62 | 2023 | 163280 | 0.390 |
Why?
|
| Sentinel Lymph Node Biopsy | 9 | 2022 | 709 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2012 | 3508 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 7 | 2021 | 2727 | 0.350 |
Why?
|
| Survival Analysis | 15 | 2019 | 10252 | 0.350 |
Why?
|
| Drug Costs | 2 | 2015 | 1105 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2022 | 5535 | 0.350 |
Why?
|
| Adult | 66 | 2022 | 214055 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 10 | 2020 | 3616 | 0.350 |
Why?
|
| Drug Therapy | 1 | 2012 | 497 | 0.350 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 1956 | 0.340 |
Why?
|
| Disclosure | 2 | 2012 | 736 | 0.340 |
Why?
|
| Filgrastim | 4 | 2020 | 133 | 0.340 |
Why?
|
| Drugs, Investigational | 1 | 2011 | 214 | 0.340 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2019 | 640 | 0.330 |
Why?
|
| Pharmacy | 1 | 2010 | 91 | 0.330 |
Why?
|
| Specialty Boards | 1 | 2010 | 227 | 0.330 |
Why?
|
| Avian Sarcoma Viruses | 6 | 1995 | 84 | 0.330 |
Why?
|
| Anemia | 3 | 2007 | 1506 | 0.330 |
Why?
|
| Critical Pathways | 1 | 2012 | 476 | 0.320 |
Why?
|
| Lymph Node Excision | 8 | 2022 | 1261 | 0.320 |
Why?
|
| Lymph Nodes | 6 | 2022 | 3474 | 0.320 |
Why?
|
| Allied Health Personnel | 1 | 2009 | 162 | 0.310 |
Why?
|
| Patients | 2 | 2012 | 900 | 0.310 |
Why?
|
| Piperidines | 3 | 2012 | 1602 | 0.300 |
Why?
|
| Carcinoma, Lobular | 3 | 2023 | 484 | 0.300 |
Why?
|
| Leuprolide | 1 | 2009 | 321 | 0.300 |
Why?
|
| Risk Assessment | 13 | 2019 | 23338 | 0.300 |
Why?
|
| Methotrexate | 6 | 2023 | 1727 | 0.300 |
Why?
|
| Hormones | 4 | 2022 | 889 | 0.290 |
Why?
|
| Quality of Life | 15 | 2022 | 12804 | 0.290 |
Why?
|
| Certification | 1 | 2010 | 424 | 0.290 |
Why?
|
| Radiotherapy | 6 | 2019 | 1533 | 0.290 |
Why?
|
| Maytansine | 2 | 2021 | 80 | 0.290 |
Why?
|
| Complementary Therapies | 3 | 2009 | 486 | 0.280 |
Why?
|
| Musculoskeletal System | 1 | 2008 | 175 | 0.280 |
Why?
|
| Survival Rate | 13 | 2019 | 12788 | 0.280 |
Why?
|
| Hormone Replacement Therapy | 2 | 2010 | 745 | 0.280 |
Why?
|
| Mammography | 5 | 2009 | 2476 | 0.280 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2005 | 358 | 0.270 |
Why?
|
| Lymphopenia | 1 | 2008 | 285 | 0.270 |
Why?
|
| Ethics, Medical | 1 | 2011 | 792 | 0.270 |
Why?
|
| Hospice Care | 1 | 2013 | 672 | 0.270 |
Why?
|
| Drug Industry | 1 | 2012 | 746 | 0.260 |
Why?
|
| Advance Care Planning | 1 | 2013 | 662 | 0.260 |
Why?
|
| Neoplasm, Residual | 3 | 2023 | 973 | 0.260 |
Why?
|
| Benchmarking | 1 | 2012 | 1042 | 0.260 |
Why?
|
| Patient Care Management | 1 | 2008 | 306 | 0.250 |
Why?
|
| Carbazoles | 1 | 2006 | 226 | 0.250 |
Why?
|
| Enzyme Inhibitors | 6 | 2011 | 3798 | 0.250 |
Why?
|
| Quinolines | 1 | 2010 | 732 | 0.250 |
Why?
|
| Fluorouracil | 7 | 2019 | 1619 | 0.240 |
Why?
|
| Checklist | 1 | 2011 | 833 | 0.240 |
Why?
|
| Physicians | 2 | 2013 | 4567 | 0.240 |
Why?
|
| Hematinics | 1 | 2007 | 281 | 0.240 |
Why?
|
| Molecular Biology | 1 | 2008 | 596 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 3 | 2012 | 2635 | 0.230 |
Why?
|
| Conflict of Interest | 1 | 2008 | 544 | 0.230 |
Why?
|
| Educational Measurement | 1 | 2010 | 1210 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2020 | 1770 | 0.230 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 1182 | 0.230 |
Why?
|
| Chromans | 1 | 2003 | 122 | 0.220 |
Why?
|
| Markov Chains | 5 | 2020 | 969 | 0.220 |
Why?
|
| Oncology Service, Hospital | 2 | 2013 | 57 | 0.220 |
Why?
|
| Erythropoiesis | 1 | 2007 | 705 | 0.220 |
Why?
|
| Gene Products, gag | 3 | 1992 | 337 | 0.220 |
Why?
|
| Pediatrics | 1 | 2018 | 3475 | 0.220 |
Why?
|
| Follow-Up Studies | 20 | 2023 | 39050 | 0.210 |
Why?
|
| Decision Making | 3 | 2020 | 3887 | 0.210 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 692 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2018 | 6538 | 0.210 |
Why?
|
| Carboplatin | 2 | 2022 | 801 | 0.210 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 2759 | 0.200 |
Why?
|
| Physician-Patient Relations | 3 | 2013 | 3229 | 0.200 |
Why?
|
| Societies, Medical | 7 | 2017 | 3743 | 0.200 |
Why?
|
| Blood Platelets | 1 | 2012 | 2508 | 0.200 |
Why?
|
| Health Care Costs | 2 | 2012 | 3209 | 0.200 |
Why?
|
| Maintenance | 1 | 2021 | 25 | 0.200 |
Why?
|
| Erythropoietin | 1 | 2005 | 726 | 0.190 |
Why?
|
| Health Policy | 2 | 2012 | 2661 | 0.190 |
Why?
|
| Amenorrhea | 3 | 2021 | 485 | 0.190 |
Why?
|
| Palliative Care | 2 | 2013 | 3493 | 0.190 |
Why?
|
| Aged, 80 and over | 21 | 2019 | 57776 | 0.190 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 1432 | 0.190 |
Why?
|
| United States | 24 | 2018 | 69872 | 0.190 |
Why?
|
| Carcinoma in Situ | 2 | 2020 | 806 | 0.180 |
Why?
|
| Mass Screening | 2 | 2021 | 5255 | 0.180 |
Why?
|
| Interleukin-4 | 3 | 1993 | 1147 | 0.180 |
Why?
|
| Patient Compliance | 1 | 2011 | 2684 | 0.180 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 476 | 0.180 |
Why?
|
| Radiodermatitis | 1 | 2000 | 60 | 0.180 |
Why?
|
| Medication Errors | 1 | 2006 | 798 | 0.180 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2002 | 255 | 0.180 |
Why?
|
| Administration, Oral | 6 | 2015 | 3913 | 0.170 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2021 | 934 | 0.170 |
Why?
|
| Disease Progression | 9 | 2011 | 13284 | 0.170 |
Why?
|
| United States Food and Drug Administration | 5 | 2018 | 1584 | 0.170 |
Why?
|
| Feasibility Studies | 3 | 2019 | 5078 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2009 | 2266 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 2455 | 0.160 |
Why?
|
| Endopeptidases | 5 | 1994 | 772 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2013 | 895 | 0.160 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 1997 | 13 | 0.150 |
Why?
|
| Disease Management | 5 | 2020 | 2459 | 0.150 |
Why?
|
| Axilla | 5 | 2022 | 595 | 0.150 |
Why?
|
| Patient Preference | 2 | 2016 | 890 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 2541 | 0.150 |
Why?
|
| Annual Reports as Topic | 1 | 2017 | 33 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2001 | 604 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14722 | 0.140 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 360 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2014 | 1534 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 4 | 2023 | 1000 | 0.140 |
Why?
|
| Time Factors | 10 | 2022 | 40075 | 0.140 |
Why?
|
| Prospective Studies | 14 | 2023 | 53288 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 624 | 0.140 |
Why?
|
| Thiazoles | 1 | 2003 | 1483 | 0.130 |
Why?
|
| Proportional Hazards Models | 8 | 2021 | 12354 | 0.130 |
Why?
|
| Fatigue | 4 | 2018 | 1531 | 0.130 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 1993 | 986 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 804 | 0.130 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 374 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 5137 | 0.130 |
Why?
|
| Research Support as Topic | 2 | 2017 | 705 | 0.130 |
Why?
|
| Early Detection of Cancer | 4 | 2017 | 3086 | 0.130 |
Why?
|
| Patient Advocacy | 2 | 2020 | 353 | 0.130 |
Why?
|
| Genetic Testing | 5 | 2019 | 3444 | 0.130 |
Why?
|
| Patient Education as Topic | 3 | 2009 | 2278 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2010 | 4687 | 0.130 |
Why?
|
| Perimenopause | 1 | 2016 | 139 | 0.120 |
Why?
|
| Cannabinoids | 1 | 2017 | 166 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 602 | 0.120 |
Why?
|
| Amniotic Fluid | 2 | 1986 | 370 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2011 | 2618 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2022 | 8324 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2009 | 4245 | 0.120 |
Why?
|
| Immune Tolerance | 2 | 1993 | 2258 | 0.110 |
Why?
|
| Cognition Disorders | 2 | 2007 | 4043 | 0.110 |
Why?
|
| HIV Protease | 4 | 1995 | 96 | 0.110 |
Why?
|
| Patient Care Team | 5 | 2013 | 2531 | 0.110 |
Why?
|
| Switzerland | 1 | 2013 | 255 | 0.110 |
Why?
|
| Consensus | 2 | 2023 | 2959 | 0.110 |
Why?
|
| Antibody Formation | 3 | 1993 | 1402 | 0.110 |
Why?
|
| Phospholipids | 2 | 1986 | 784 | 0.110 |
Why?
|
| Gene Products, pol | 1 | 1992 | 47 | 0.110 |
Why?
|
| Age Factors | 6 | 2019 | 18370 | 0.110 |
Why?
|
| Platelet Factor 4 | 1 | 2012 | 129 | 0.110 |
Why?
|
| Anonymous Testing | 1 | 2011 | 8 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2014 | 549 | 0.100 |
Why?
|
| Genes, gag | 1 | 1991 | 61 | 0.100 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2011 | 115 | 0.100 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2011 | 38 | 0.100 |
Why?
|
| Risk Factors | 15 | 2022 | 72290 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2010 | 288 | 0.100 |
Why?
|
| Genotype | 4 | 2019 | 12951 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 162 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 10943 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2018 | 555 | 0.100 |
Why?
|
| Interdisciplinary Communication | 4 | 2013 | 950 | 0.100 |
Why?
|
| Environment Design | 1 | 2013 | 178 | 0.100 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 676 | 0.100 |
Why?
|
| Dyspnea | 1 | 2019 | 1303 | 0.100 |
Why?
|
| Hematologic Diseases | 2 | 2008 | 498 | 0.100 |
Why?
|
| Self Report | 3 | 2018 | 3558 | 0.090 |
Why?
|
| Advisory Committees | 3 | 2010 | 775 | 0.090 |
Why?
|
| Dissent and Disputes | 1 | 2011 | 141 | 0.090 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1991 | 246 | 0.090 |
Why?
|
| Congresses as Topic | 2 | 2012 | 764 | 0.090 |
Why?
|
| Inservice Training | 1 | 2013 | 392 | 0.090 |
Why?
|
| Body Weight | 1 | 2021 | 4669 | 0.090 |
Why?
|
| Nausea | 2 | 2017 | 673 | 0.090 |
Why?
|
| Retrospective Studies | 12 | 2023 | 77449 | 0.090 |
Why?
|
| New York | 1 | 2012 | 886 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2006 | 841 | 0.090 |
Why?
|
| Cognition | 1 | 2007 | 6770 | 0.090 |
Why?
|
| Quality of Health Care | 3 | 2012 | 4371 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2019 | 685 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 552 | 0.090 |
Why?
|
| Electronic Mail | 1 | 2011 | 213 | 0.090 |
Why?
|
| Fertility | 2 | 2016 | 781 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 2866 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 6622 | 0.080 |
Why?
|
| Lymphocyte Activation | 4 | 1993 | 5524 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 9438 | 0.080 |
Why?
|
| California | 1 | 2012 | 1402 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2011 | 551 | 0.080 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 6364 | 0.080 |
Why?
|
| Marketing of Health Services | 1 | 2009 | 153 | 0.080 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2008 | 61 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2015 | 2274 | 0.080 |
Why?
|
| Heart Diseases | 3 | 2010 | 2788 | 0.080 |
Why?
|
| Endpoint Determination | 2 | 2012 | 601 | 0.080 |
Why?
|
| Young Adult | 9 | 2021 | 56430 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2015 | 629 | 0.080 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 417 | 0.080 |
Why?
|
| Therapies, Investigational | 1 | 2008 | 112 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 3 | 1992 | 1990 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 1125 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2011 | 430 | 0.070 |
Why?
|
| Ultrasonography, Mammary | 1 | 2009 | 250 | 0.070 |
Why?
|
| Waiting Lists | 1 | 2011 | 692 | 0.070 |
Why?
|
| Sarcoma | 1 | 2019 | 1897 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2020 | 3748 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2023 | 12720 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2008 | 376 | 0.070 |
Why?
|
| Mutation | 6 | 2023 | 29786 | 0.070 |
Why?
|
| Vasodilation | 1 | 2011 | 944 | 0.070 |
Why?
|
| Home Care Services | 1 | 2013 | 606 | 0.070 |
Why?
|
| Policy | 1 | 2010 | 508 | 0.070 |
Why?
|
| Antigens | 1 | 1992 | 1466 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2019 | 3821 | 0.070 |
Why?
|
| Sphingomyelins | 1 | 1986 | 105 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 595 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2011 | 623 | 0.070 |
Why?
|
| Cooperative Behavior | 2 | 2010 | 1504 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 13102 | 0.070 |
Why?
|
| Genetic Techniques | 1 | 2009 | 435 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2014 | 2740 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2006 | 403 | 0.070 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 432 | 0.070 |
Why?
|
| Pulmonary Surfactants | 1 | 1986 | 162 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2012 | 2029 | 0.070 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 3670 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 389 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1205 | 0.060 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2006 | 249 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2014 | 4217 | 0.060 |
Why?
|
| Predictive Value of Tests | 5 | 2008 | 15076 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2016 | 5007 | 0.060 |
Why?
|
| Awareness | 1 | 2009 | 640 | 0.060 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 104 | 0.060 |
Why?
|
| Algorithms | 5 | 2012 | 13881 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 2073 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2009 | 670 | 0.060 |
Why?
|
| Exercise | 1 | 2021 | 5615 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2017 | 5097 | 0.060 |
Why?
|
| Imidazoles | 1 | 2011 | 1206 | 0.060 |
Why?
|
| Preoperative Care | 3 | 2008 | 2250 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5317 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2000 | 4558 | 0.060 |
Why?
|
| Obesity | 3 | 2023 | 12745 | 0.060 |
Why?
|
| Europe | 1 | 2011 | 3339 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2006 | 1677 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8388 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1992 | 1838 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 5391 | 0.060 |
Why?
|
| Periodontitis | 1 | 2008 | 553 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2015 | 1596 | 0.060 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 773 | 0.060 |
Why?
|
| Alopecia | 1 | 2007 | 382 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 3143 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1660 | 0.060 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 1701 | 0.060 |
Why?
|
| Incidence | 3 | 2020 | 20947 | 0.060 |
Why?
|
| Remission Induction | 2 | 2008 | 2386 | 0.060 |
Why?
|
| Genomics | 2 | 2019 | 5720 | 0.060 |
Why?
|
| Carcinoma, Ductal | 2 | 2019 | 101 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2009 | 1530 | 0.050 |
Why?
|
| Constipation | 1 | 2007 | 546 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1986 | 546 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2011 | 1058 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 1011 | 0.050 |
Why?
|
| Perception | 1 | 2009 | 1198 | 0.050 |
Why?
|
| Age of Onset | 1 | 2009 | 3271 | 0.050 |
Why?
|
| Trinitrobenzenes | 2 | 1992 | 46 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2006 | 2649 | 0.050 |
Why?
|
| Vinca Alkaloids | 1 | 2002 | 35 | 0.050 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2012 | 1209 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 2879 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 2559 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2011 | 2132 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2009 | 6234 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2002 | 152 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 4262 | 0.050 |
Why?
|
| Biology | 1 | 2024 | 294 | 0.050 |
Why?
|
| Platinum Compounds | 1 | 2002 | 96 | 0.050 |
Why?
|
| Recurrence | 3 | 2020 | 8340 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2004 | 730 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 1993 | 4665 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 11366 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 2716 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2016 | 3749 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 65 | 0.050 |
Why?
|
| Thiotepa | 1 | 2001 | 66 | 0.050 |
Why?
|
| Epothilones | 1 | 2021 | 44 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 2 | 2009 | 2212 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2008 | 1640 | 0.050 |
Why?
|
| Epirubicin | 1 | 2001 | 80 | 0.050 |
Why?
|
| Breast | 3 | 2023 | 1969 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2012 | 1901 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2005 | 1063 | 0.050 |
Why?
|
| Terminal Care | 1 | 2013 | 1694 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2012 | 9849 | 0.050 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1991 | 318 | 0.050 |
Why?
|
| Premedication | 1 | 2021 | 258 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 565 | 0.050 |
Why?
|
| Ovalbumin | 2 | 1993 | 719 | 0.050 |
Why?
|
| Bone Density | 2 | 2011 | 3468 | 0.050 |
Why?
|
| Syndrome | 1 | 2007 | 3251 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2014 | 12026 | 0.050 |
Why?
|
| Cisplatin | 2 | 2009 | 1662 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2005 | 921 | 0.050 |
Why?
|
| Inpatients | 1 | 2011 | 2518 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 1993 | 1827 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2005 | 1609 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2021 | 644 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1170 | 0.040 |
Why?
|
| International Agencies | 1 | 2020 | 240 | 0.040 |
Why?
|
| Research | 1 | 2008 | 1999 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2001 | 408 | 0.040 |
Why?
|
| Proteomics | 1 | 2012 | 3638 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2002 | 297 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2015 | 4445 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 1991 | 9734 | 0.040 |
Why?
|
| Truth Disclosure | 1 | 2003 | 436 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 4456 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 6489 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2007 | 884 | 0.040 |
Why?
|
| Osteoporosis | 2 | 2014 | 1580 | 0.040 |
Why?
|
| Animals | 12 | 2014 | 168757 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2003 | 575 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 542 | 0.040 |
Why?
|
| Liposomes | 1 | 2001 | 759 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2942 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2019 | 513 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2009 | 3923 | 0.040 |
Why?
|
| Lung | 2 | 1986 | 9856 | 0.040 |
Why?
|
| Heart Failure | 2 | 2012 | 10900 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 1832 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 4 | 1995 | 1723 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2009 | 2063 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 210 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 203 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 1993 | 10180 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2007 | 1352 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 4560 | 0.040 |
Why?
|
| Proteins | 1 | 1992 | 6103 | 0.040 |
Why?
|
| Fetal Organ Maturity | 2 | 1986 | 82 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 1792 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2021 | 850 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2009 | 2348 | 0.030 |
Why?
|
| Retreatment | 1 | 2018 | 610 | 0.030 |
Why?
|
| Fluorescence Polarization | 2 | 1986 | 132 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 17446 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2001 | 1460 | 0.030 |
Why?
|
| Research Design | 1 | 2012 | 5987 | 0.030 |
Why?
|
| ROC Curve | 1 | 2003 | 3527 | 0.030 |
Why?
|
| Interleukin-2 | 2 | 1993 | 1904 | 0.030 |
Why?
|
| Data Collection | 2 | 2008 | 3341 | 0.030 |
Why?
|
| Mammaplasty | 2 | 2016 | 1204 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2013 | 40561 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1180 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 3843 | 0.030 |
Why?
|
| Models, Biological | 1 | 2011 | 9583 | 0.030 |
Why?
|
| Phosphatidylcholines | 2 | 1986 | 411 | 0.030 |
Why?
|
| Random Allocation | 1 | 1999 | 2429 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 8863 | 0.030 |
Why?
|
| Body Height | 1 | 2021 | 1577 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2000 | 787 | 0.030 |
Why?
|
| Estrogens | 1 | 2021 | 1566 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 2003 | 1241 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2006 | 3589 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 1993 | 3206 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2023 | 2072 | 0.030 |
Why?
|
| Male | 13 | 2023 | 350118 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 911 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 492 | 0.030 |
Why?
|
| Hospitalization | 1 | 2013 | 10262 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2016 | 618 | 0.030 |
Why?
|
| Federal Government | 1 | 2015 | 260 | 0.030 |
Why?
|
| Triage | 1 | 2020 | 976 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 1995 | 311 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1782 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 564 | 0.030 |
Why?
|
| Comorbidity | 1 | 2007 | 10388 | 0.030 |
Why?
|
| Alpharetrovirus | 1 | 1992 | 31 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1993 | 158 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12959 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 781 | 0.030 |
Why?
|
| Boston | 1 | 2005 | 9313 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2000 | 1061 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 2 | 2009 | 1344 | 0.030 |
Why?
|
| Menopause | 1 | 2000 | 1626 | 0.030 |
Why?
|
| Haptens | 1 | 1992 | 166 | 0.030 |
Why?
|
| Income | 1 | 2021 | 1913 | 0.030 |
Why?
|
| Antigens, T-Independent | 1 | 1991 | 21 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 1184 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 35421 | 0.030 |
Why?
|
| Overweight | 1 | 2023 | 2371 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2011 | 23403 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 127 | 0.030 |
Why?
|
| HIV-1 | 3 | 1995 | 6939 | 0.030 |
Why?
|
| Lymphocyte Cooperation | 1 | 1991 | 112 | 0.030 |
Why?
|
| Fever | 2 | 2011 | 1616 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2006 | 5102 | 0.020 |
Why?
|
| Financing, Government | 1 | 2015 | 468 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 2109 | 0.020 |
Why?
|
| Gene Expression | 1 | 2003 | 7799 | 0.020 |
Why?
|
| Amino Acid Sequence | 5 | 1995 | 13815 | 0.020 |
Why?
|
| Solubility | 1 | 1992 | 1085 | 0.020 |
Why?
|
| Kinetics | 3 | 1995 | 6473 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2015 | 553 | 0.020 |
Why?
|
| Child | 1 | 2018 | 77709 | 0.020 |
Why?
|
| Health Status | 1 | 2003 | 4034 | 0.020 |
Why?
|
| Drug Information Services | 1 | 2009 | 51 | 0.020 |
Why?
|
| Molecular Sequence Data | 5 | 1995 | 18111 | 0.020 |
Why?
|
| Keratin-19 | 1 | 2009 | 33 | 0.020 |
Why?
|
| Apoptosis | 1 | 2005 | 9727 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1915 | 0.020 |
Why?
|
| Substrate Specificity | 4 | 1995 | 1801 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 1912 | 0.020 |
Why?
|
| Cell Line | 3 | 1992 | 15997 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1991 | 1454 | 0.020 |
Why?
|
| Developing Countries | 1 | 2021 | 2815 | 0.020 |
Why?
|
| Immunomagnetic Separation | 1 | 2009 | 80 | 0.020 |
Why?
|
| Evidence-Based Medicine | 3 | 2009 | 3610 | 0.020 |
Why?
|
| Prevalence | 1 | 2005 | 15226 | 0.020 |
Why?
|
| Protein Precursors | 1 | 1992 | 1154 | 0.020 |
Why?
|
| Pregnancy | 3 | 2002 | 29144 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7474 | 0.020 |
Why?
|
| Alveolar Process | 1 | 2008 | 293 | 0.020 |
Why?
|
| Polyglutamic Acid | 1 | 2007 | 44 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1023 | 0.020 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1986 | 81 | 0.020 |
Why?
|
| Phosphatidylglycerols | 1 | 1986 | 34 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3597 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2014 | 1167 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 892 | 0.020 |
Why?
|
| Risk | 1 | 2019 | 9687 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 933 | 0.020 |
Why?
|
| Cell Communication | 1 | 1993 | 1621 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 2307 | 0.020 |
Why?
|
| Phosphatidylethanolamines | 1 | 1986 | 134 | 0.020 |
Why?
|
| Water | 1 | 1992 | 1395 | 0.020 |
Why?
|
| Flavonoids | 1 | 2009 | 443 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1876 | 0.020 |
Why?
|
| Alveolar Bone Loss | 1 | 2008 | 383 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 1986 | 588 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 1999 | 7785 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 1991 | 1463 | 0.020 |
Why?
|
| Antiemetics | 1 | 2006 | 177 | 0.020 |
Why?
|
| Paget's Disease, Mammary | 1 | 1964 | 19 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3508 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2008 | 729 | 0.020 |
Why?
|
| Osteitis Deformans | 1 | 1964 | 53 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 2892 | 0.020 |
Why?
|
| Paget Disease, Extramammary | 1 | 1964 | 45 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2013 | 2682 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 20129 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1986 | 981 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3870 | 0.010 |
Why?
|
| Dependovirus | 1 | 2008 | 706 | 0.010 |
Why?
|
| Transfection | 1 | 1991 | 5892 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5319 | 0.010 |
Why?
|
| Medicare | 2 | 2016 | 6566 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 13989 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 6314 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 163 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 19905 | 0.010 |
Why?
|
| Telemedicine | 1 | 2020 | 2872 | 0.010 |
Why?
|
| Review Literature as Topic | 1 | 2004 | 336 | 0.010 |
Why?
|
| Prednisone | 1 | 2006 | 1574 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1994 | 708 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1991 | 3748 | 0.010 |
Why?
|
| Base Sequence | 2 | 2009 | 12797 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 3846 | 0.010 |
Why?
|
| Pathology | 1 | 1964 | 272 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2008 | 1184 | 0.010 |
Why?
|
| Sirolimus | 1 | 2008 | 1564 | 0.010 |
Why?
|
| Mice | 3 | 1993 | 81183 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2009 | 1099 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1991 | 5974 | 0.010 |
Why?
|
| Binding Sites | 3 | 1995 | 6114 | 0.010 |
Why?
|
| Organizational Policy | 1 | 2003 | 429 | 0.010 |
Why?
|
| Protein Conformation | 3 | 1994 | 4011 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1991 | 4026 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12261 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2011 | 21746 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15519 | 0.010 |
Why?
|
| Depression | 1 | 1999 | 7766 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2006 | 1951 | 0.010 |
Why?
|
| Cardiology | 1 | 2010 | 1668 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 972 | 0.010 |
Why?
|
| Calcium | 1 | 1992 | 5756 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2008 | 3420 | 0.010 |
Why?
|
| Point Mutation | 2 | 1995 | 1623 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2011 | 19229 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1991 | 4386 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 2282 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 2016 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 41006 | 0.010 |
Why?
|
| Lymphoma | 1 | 2007 | 1877 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2001 | 15165 | 0.010 |
Why?
|
| SEER Program | 1 | 2003 | 1508 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 8301 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4253 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 3396 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 1790 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 4149 | 0.010 |
Why?
|
| Pain | 1 | 2011 | 4986 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8554 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 7322 | 0.010 |
Why?
|
| Patient Participation | 1 | 2003 | 1457 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1994 | 878 | 0.010 |
Why?
|
| X-Ray Diffraction | 1 | 1994 | 420 | 0.010 |
Why?
|
| Catalysis | 1 | 1995 | 761 | 0.010 |
Why?
|
| Coturnix | 1 | 1992 | 21 | 0.010 |
Why?
|
| Turkeys | 1 | 1992 | 48 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 85781 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1992 | 173 | 0.010 |
Why?
|
| Leukemia | 1 | 2001 | 1511 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 24260 | 0.010 |
Why?
|
| Models, Molecular | 2 | 1992 | 5456 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 11124 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 11483 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1992 | 718 | 0.010 |
Why?
|
| Weight Gain | 1 | 2001 | 2292 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1995 | 2011 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1991 | 342 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 12245 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 5221 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1991 | 973 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1991 | 805 | 0.000 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 6773 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 4320 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1994 | 4186 | 0.000 |
Why?
|